Best Life Sciences Companies in Victoria, Australia

Mesoblast specializes in developing cellular medicines. The company has a clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. These clinical programs target therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The Japanese Government has approved TEMCELL® HS. Inj., a product based on their proprietary allogeneic mesenchymal lineage adult stem cell technology licensed to JCR Pharmaceuticals Co. Ltd for the treatment of graft versus host disease in children and adults in Japan. Their product candidate, MSC-100-IV, has orphan drug designation and is being developed under an accelerated regulatory approval pathway in line with the United States Food and Drug Administration (FDA) discussions for children with steroid-refractory acute graft versus host disease. Two other lead product candidates, MPC-150-IM and MPC-06-ID, are in late-stage development in Phase 3 programs targeting, respectively, advanced chronic heart failure and chronic low bac

Developer of AI-powered CT imaging solutions. The company is developing AI-based weight-bearing CT (WBCT) imaging systems for the orthopedic and musculoskeletal (MSK) specialties for the diagnosis of lower extremity conditions.

Funding rounds

• Feb 2026Post IPO$2.8M
• Feb 2023Series A$25M
• Nov 2022Seed$255.4K

Founders & team

Arun SinghCEO

Investors

Tenmile, Firetrail, Karst Peak Capital, Ilwella

Tech stack

Amazon SesAmazon Web ServicesAnimate.CssAutoptimizeCalendlyClickdimensions

{}

Funding rounds

• Oct 2025Series B$22.4M
• Feb 2025Series B$5M
• Jun 2021Series B$25M

Founders & team

Christophe DemaisonManaging Director

Investors

Uniseed, Minderoo Foundation, Brandon Capital, Flu Lab, Gates, Stoic Venture Capital

Developer of antiviral therapeutics for infectious diseases. The lead drug candidate ISLA-101 is repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases. It prevents nuclear entry of the viral protein that prevents propagation of the viral infection.

Funding rounds

• Feb 2026Post IPO$6.3M
• Mar 2024Post IPO$1.2M

Founders & team

David FosterChief Executive Officer and Managing Director

Investors

Alium Capital

Tech stack

CdnjsCloudflareFancyboxFont AwesomeGoogle AnalyticsGoogle Font Api

Opthea develops and commercializes protein therapies for ophthalmology. Its approach includes targeting the Vascular Endothelial Growth Factor (VEGF) protein family, specifically VEGF-C, VEGF-D, and VEGFR-3. Its lead candidate, a soluble form of VEGF-3, is currently in phase I/IIA trials for the treatment of wet age-related macular degeneration.

Funding rounds

• Mar 2025Post IPO—
• Aug 2022Post IPO$90.2M
• Oct 2019Conventional Debt$9.9M
• Apr 2017Post IPO$33.6M

Founders & team

Frederic GuerardChief Executive Officer

Investors

Biopharm Australia, ATO, JPMorgan Chase, Abingworth, The Carlyle Group

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Provider of therapies to treat neurodegenerative disease. The company's drugs include PBT434 is meant for Parkinsonian disorders and is being evaluated in clinical trials. The drug is a small molecule designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain.

Funding rounds

• Sep 2025Post IPO$13.1M
• Feb 2021Grant (prize money)$495K
• May 2008Post IPO$6.7M
• Post IPO—

Founders & team

David StamlerChief Executive Officer

Investors

The Michael J. Fox Foundation

Developer of therapeutics for neurodegenerative diseases. The pipeline includes NUZ-001S-Monepante which targets and address the underlying mechanisms of neurodegenerative disease and treat Amyotrophic lateral sclerosis.

Funding rounds

• Feb 2026Post IPO$3.6M

Founders & team

Michael ThurnCEO & Managing Director

Investors

Obsidiangp

Tech stack

Animate.CssAnime.JsBackbone.JsCloudflareFancyboxFont Awesome

PolyActiva has developed a platform technology for slow-release, site-specific drug delivery. Upon the application of the treatment, complete erosion of the implant occurs leaving no residue following drug release. This technology can be used to produce new biomedical products, drug-delivery devices and device components that enable delivery of drugs directly to the affected organ or treatment site. They are produced from a proprietary drug-polymer conjugate technology. Products are being developed for glaucoma, endophthalmitis, and osteoarthritis.

Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer. The company has an hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes.

Funding rounds

• Oct 2025Post IPO$6.1M

Founders & team

Leearne HinchCEO

Investors

Cmhg

Tech stack

Amazon ElbAmazon Web ServicesCart FunctionalityCdnjsCloudflareCloudflare Browser Insights

Developer of a platform for personalized chemotherapy dosing using body analysis. The platform analyzes CT scans to segment muscle, fat, bone, and tumor volume. This creates a detailed body composition profile for each patient. Machine learning models then predict the optimal chemotherapy dose before the first cycle.

Funding rounds

• Oct 2025Seed$1.6M

Founders & team

Justin YeungCo-Founder & CMOAbhijeet WaykarCo-Founder & CEO & CTO

Incannex is a clinical stage pharmaceutical company that specializes in the development of medicinal cannabinoid compounds and psychedelic therapies. They have a diversified portfolio of 28 FDA compliant R&D programs and are well positioned as a leader in the development of novel cannabinoid pharmaceuticals and psychedelic therapies.

Funding rounds

• Mar 2025Post IPO$12.5M

Founders & team

Joel LathamCEO & MD

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Manufacturer of radiopharmaceutical products for diagnostic test

Funding rounds

• Jul 2024Post IPO$45.8M
• Feb 2024Post IPO—

Founders & team

Paul HopperExecutive Chairman & FounderRiccardo CanevariChief Executive Officer

Investors

The Lind Partners, Lantheus

Tech stack

Amazon SesAmazon Web ServicesBootstrapContact Form 7Core-JsDocusign